Thoughts on systemic treatment of bone metastases in prostate cancer patients
DOI: 10.22591/magyurol.2022.3.pikob.107
Authors:
Pikó Béla dr.1, Kis Anita dr. 1, Bassam Ali dr.1, Molnár Zsanett1, Ovidiu Rus-Gal Paul dr.1, Szeberényi Tamás dr.2, Mészáros Tibor dr.2
1 Békés Megyei Központi Kórház, Tagkórház Pándy Kálmán, Megyei Onkológiai Központ, Gyula (osztályvezető: Pikó Béla dr.)
2Békés Megyei Központi Kórház, Tagkórház Pándy Kálmán, Urológiai Osztály, Gyula (osztályvezető: Mészáros Tibor dr.)
Summary
Prostate cancer is a serious public health issue; which treatment possibilities are constantly developing. Metastases are common, and the vast majority, up to 90%, alone or in combination with other localizations, are bone metastases. The authors briefly describe the molecular mechanism of cancer formation and the possibilities of imaging diagnostics. They emphasize the importance of the Onko-team during the treatment and the therapeutic options, even, when there is no further active therapy, and also some aspects of the legislation that prescribes its process, and their practical significance. The treatment of bone metastases (in addition to the standard therapy of the malignancy) includes systemic therapy in almost all cases beside the local surgical and radiotherapeutic interventions. They present zoledronic acid (the only bisphosphonate with proven efficacy), denosumab acting on the “Receptor activator of NF-kB “[RANK] system”, alpha and beta emitting isotopes, as well as the important aspects of day-to-day patient care and side effects. They emphasize the interdisciplinary nature of palliative medicine, the adaptation of the patient’s environment to the patient’s needs, and also the importance of beginning the treatment as soon as possible.